Cargando…
Rapidly Progressive Lung Sarcomatoid Carcinoma Managed with Doxorubicin Plus Ifosfamide and Pemetrexed
Pulmonary sarcomatoid carcinoma (PSC) is a rare subtype of nonsmall-cell lung cancer (NSCLC). It carries a poor prognosis, even among other subtypes of NSCLC. Currently, most treatment strategies for PSC are derived from regimens aimed at managing soft tissue sarcomas or NSCLC. The use of doxorubici...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
S. Karger AG
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8740224/ https://www.ncbi.nlm.nih.gov/pubmed/35082625 http://dx.doi.org/10.1159/000520190 |
_version_ | 1784629266707644416 |
---|---|
author | Paredes Mogica, Jan Alberto Reyes Sanchez, Eduardo Zaragoza Morales, Daniela Arantza Pierre-Louis Guillen, Nathalie Magallanes Maciel, Manuel Ernesto |
author_facet | Paredes Mogica, Jan Alberto Reyes Sanchez, Eduardo Zaragoza Morales, Daniela Arantza Pierre-Louis Guillen, Nathalie Magallanes Maciel, Manuel Ernesto |
author_sort | Paredes Mogica, Jan Alberto |
collection | PubMed |
description | Pulmonary sarcomatoid carcinoma (PSC) is a rare subtype of nonsmall-cell lung cancer (NSCLC). It carries a poor prognosis, even among other subtypes of NSCLC. Currently, most treatment strategies for PSC are derived from regimens aimed at managing soft tissue sarcomas or NSCLC. The use of doxorubicin plus ifosfamide and pemetrexed has been well established in the management of soft tissue carcinoma and other nonsmall-cell lung cancers, respectively. We report the case of a 69-year-old male diagnosed with PSC who was managed with doxorubicin plus ifosfamide and pemetrexed therapy. Our patient initially responded to the therapy but had rapid progression and died 8 months after the initiation of treatment. Upon genetic analysis, it was revealed the patient had overexpression of the MDM2 protein, which has been associated with poor response to therapy. This case highlights the need for a personalized treatment approach, as well as the need for a standardized treatment regimen for managing PSC. |
format | Online Article Text |
id | pubmed-8740224 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | S. Karger AG |
record_format | MEDLINE/PubMed |
spelling | pubmed-87402242022-01-25 Rapidly Progressive Lung Sarcomatoid Carcinoma Managed with Doxorubicin Plus Ifosfamide and Pemetrexed Paredes Mogica, Jan Alberto Reyes Sanchez, Eduardo Zaragoza Morales, Daniela Arantza Pierre-Louis Guillen, Nathalie Magallanes Maciel, Manuel Ernesto Case Rep Oncol Case Report Pulmonary sarcomatoid carcinoma (PSC) is a rare subtype of nonsmall-cell lung cancer (NSCLC). It carries a poor prognosis, even among other subtypes of NSCLC. Currently, most treatment strategies for PSC are derived from regimens aimed at managing soft tissue sarcomas or NSCLC. The use of doxorubicin plus ifosfamide and pemetrexed has been well established in the management of soft tissue carcinoma and other nonsmall-cell lung cancers, respectively. We report the case of a 69-year-old male diagnosed with PSC who was managed with doxorubicin plus ifosfamide and pemetrexed therapy. Our patient initially responded to the therapy but had rapid progression and died 8 months after the initiation of treatment. Upon genetic analysis, it was revealed the patient had overexpression of the MDM2 protein, which has been associated with poor response to therapy. This case highlights the need for a personalized treatment approach, as well as the need for a standardized treatment regimen for managing PSC. S. Karger AG 2021-11-25 /pmc/articles/PMC8740224/ /pubmed/35082625 http://dx.doi.org/10.1159/000520190 Text en Copyright © 2021 by S. Karger AG, Basel https://creativecommons.org/licenses/by-nc/4.0/This article is licensed under the Creative Commons Attribution-NonCommercial-4.0 International License (CC BY-NC) (http://www.karger.com/Services/OpenAccessLicense). Usage and distribution for commercial purposes requires written permission. |
spellingShingle | Case Report Paredes Mogica, Jan Alberto Reyes Sanchez, Eduardo Zaragoza Morales, Daniela Arantza Pierre-Louis Guillen, Nathalie Magallanes Maciel, Manuel Ernesto Rapidly Progressive Lung Sarcomatoid Carcinoma Managed with Doxorubicin Plus Ifosfamide and Pemetrexed |
title | Rapidly Progressive Lung Sarcomatoid Carcinoma Managed with Doxorubicin Plus Ifosfamide and Pemetrexed |
title_full | Rapidly Progressive Lung Sarcomatoid Carcinoma Managed with Doxorubicin Plus Ifosfamide and Pemetrexed |
title_fullStr | Rapidly Progressive Lung Sarcomatoid Carcinoma Managed with Doxorubicin Plus Ifosfamide and Pemetrexed |
title_full_unstemmed | Rapidly Progressive Lung Sarcomatoid Carcinoma Managed with Doxorubicin Plus Ifosfamide and Pemetrexed |
title_short | Rapidly Progressive Lung Sarcomatoid Carcinoma Managed with Doxorubicin Plus Ifosfamide and Pemetrexed |
title_sort | rapidly progressive lung sarcomatoid carcinoma managed with doxorubicin plus ifosfamide and pemetrexed |
topic | Case Report |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8740224/ https://www.ncbi.nlm.nih.gov/pubmed/35082625 http://dx.doi.org/10.1159/000520190 |
work_keys_str_mv | AT paredesmogicajanalberto rapidlyprogressivelungsarcomatoidcarcinomamanagedwithdoxorubicinplusifosfamideandpemetrexed AT reyessanchezeduardo rapidlyprogressivelungsarcomatoidcarcinomamanagedwithdoxorubicinplusifosfamideandpemetrexed AT zaragozamoralesdanielaarantza rapidlyprogressivelungsarcomatoidcarcinomamanagedwithdoxorubicinplusifosfamideandpemetrexed AT pierrelouisguillennathalie rapidlyprogressivelungsarcomatoidcarcinomamanagedwithdoxorubicinplusifosfamideandpemetrexed AT magallanesmacielmanuelernesto rapidlyprogressivelungsarcomatoidcarcinomamanagedwithdoxorubicinplusifosfamideandpemetrexed |